PubMed Health⌕ Search

PubMed · 7777723

Pheochromocytoma.

Abstract

Although a rare cause of secondary hypertension, timely recognition and management of pheochromocytoma are crucial to prevent serious complications that can result from this tumor. The cause of pheochromocytoma is unknown. It may be a component of a polyglandular endocrine disturbance or associated with other neuroectodermal tumors, but usually it is recognized as an isolated finding. Because of the variable clinical manifestations, proper diagnostic quest for pheochromocytoma depends on a high index of suspicion. Availability of biochemical assays for catecholamines and their metabolites has improved our ability to establish or exclude the diagnosis of pheochromocytoma in a suspected patient. However, before ordering the biochemical tests, it is important to be certain that the patient has not taken any drugs or substances that can lead to a spurious value. Confirmatory localization of pheochromocytoma has become a straightforward exercise owing to current radiological techniques. Blockade of the effects of catecholamines provides the pharmacological basis for medical treatment of pheochromocytoma. Surgical removal of the tumor is the treatment of choice for most patients with pheochromocytoma.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C V Ram, G A Fierro-Carrion. 1995. Pheochromocytoma.. https://pubmed.ncbi.nlm.nih.gov/7777723/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients.

Adrenal Gland Neoplasms↗

Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene.

INTRODUCTION: Malignant paragangliomas have been well described in carriers of mutations of the succinate dehydrogenase B (SDHB) gene, but have rarely been associated with mutations in the succinate dehydrogenase D (SDHD) gene. AIM: The aim of the study was to report the different clinical expression patterns of malignant paragangliomas in five patients with SDHD (D92Y) mutations observed in approximately 200 SDHD (D92Y) mutation carriers followed in our institution. RESULTS: Metastasis and/or local tumor invasion was documented 0 (n=2), 1, 18, and 30 yr after the initial diagnosis of paraganglioma. Malignancy was proven by paraganglioma bone metastases (n=2), intrathoracic paraganglioma with lymph node metastases, locally invasive head-and-neck paraganglioma with destruction of the petrosal bone, and locally invasive paraganglioma of the bladder with lymph node metastases. Four of the five patients developed catecholamine excess during follow-up due to intraadrenal paraganglioma (pheochromocytoma) (n=1), extra adrenal paraganglioma (n=2), and presumed subclinical disease (n=1). CONCLUSION: SDHD mutations (D92Y) are associated with malignant paragangliomas and catecholamine excess with remarkable interindividual variations despite the same mutation. We estimate that the prevalence of malignancy in carriers of D92Y mutations is at least 2.5%.

Adrenal Gland Neoplasms↗